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ABSTRACT

The presently-disclosed subject matter includes compounds
that comprise an initiator and an active agent that is covalently bonded to the initiator through a ring-opening polymerization process, an atom-transfer radical polymerization
process, a Michael addition reaction, or a ring-opening
metathesis polymerization process. In some embodiments
the active agent includes simvastatin. The presently-disclosed subject matter also includes methods for making the
compositions and methods for using the compositions to
treat tissue wounds.
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POLYMERIC PRODRUG

encapsulated in polymers. Entrapment in a solid matrix
protects the molecules from enviroumental effects, and
controlled release can be achieved. Persistent challenges,
however, include instability of encapsulated drugs, incomplete release, and initial burst.
Therefore, since cells and tissues require exposure to
bioactive agents at particular concentrations and doses for
certain durations, limited release kinetics is a shortcoming of
many drug delivery systems in regenerative medicine. Consequently, some have attempted to develop drugs conjugated
to polymers to extend release duration. Among others, water
soluble polymers, such as poly(ethylene glycol), polylysine,
polyglutamic acid, and N-(2-hydroxypropyl)methacrylamide (HPMA) have been used for this purpose. With these
systems, drugs are attached as pendants linked to the polymeric backbone via ester, amide, and hydrazone bonds.
Depending on the spacer molecule chosen, drug release can
be prolonged until cleavage in a desired environment, such
as pH-sensitive release in a lysosome. Other applications
include targeting to specific cells and prolonging circulation
time by shielding the drug from degradative enzymes and
preventing opsonization. The number of molecules (i.e.,
payload) that can be attached to the backbone, however, is
limited by the number of functional groups required for
conjugation.
Hence, there remains a need for degradable compositions
and compounds for treating tissue wounds, including bone
tissue wounds, that can release drugs at a wound site in a
controlled manner. There also remains a need for such
compositions and compounds whose payload is not limited
by the number of functional groups present on a polymer
backbone.

RELATED APPLICATIONS
This Application claims the benefit of U.S. Provisional
Patent Application No. 61/885,915, filed Oct. 2, 2013, the
entire disclosure of which is hereby incorporated by reference.
GOVERNMENT SUPPORT
This invention was made with govermnent support under
grant number DGE-0653710 awarded by National Science
Foundation (NSF). The govermnent has certain rights in the
invention.
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TECHNICAL FIELD
The present invention generally relates to polymeric prodrugs. In particular, certain embodiments of the present
invention relate to polymer compounds that degrade to
release an active agent.

20

BACKGROUND
25

The need to treat bone defects resulting from age-related
degenerative disease, trauma, and reconstructive surgery
continues to grow at a significant rate. An estimated 2.2
million bone grafting procedures are performed annually
worldwide at a cost of $2.5 billion. Considering the "graying" of the U.S. population, in which the percentage of
persons 55 years and older is expected to nearly double over
the next 30 years, tremendous societal impact is inevitable.
Consequently, the market for orthopedic biomaterials will
continue to expand.
Autologous (i.e., autografts) and cadaveric (i.e.,
allografts) bone are the most cormnonly used grafting materials to treat bone defects. Each, however, has drawbacks
related to morbidity associated with a second surgical procedure for autografts and the potential for disease transmissian with allografts. These observations have led to development of synthetic materials and tissue engineering
approaches for use in bone regeneration. Bone graft substitutes have used materials of natural and synthetic origin.
Ongoing developments focus on enhancing biological activity, such as by incorporating stem cells (e.g., mesenchymal
stem cells) and growth factors (e.g., bone morphogenetic
protein (BMP) 2) into bone graft substitute materials.
Synthetic biodegradable polymers are also used for drug
delivery and to aid in tissue regeneration. Candidate materials include polyanhydrides, polyamides, polycarbonates,
and polyorthoesters. The majority of resorbable synthetic
polymers utilized for drug delivery and tissue engineering
belong to the polyester family, such as poly(glycolic acid),
poly(lactic acid), and poly(lactic-co-glycolic acid) (PLGA).
These materials are relatively biocompatible, can degrade by
the hydrolytic cleavage of ester bonds, and have degradation
and mechanical properties that can be tailored by changing
monomer ratio. Their degradation products of glycolic and
lactic acid are metabolically removed from the body by
conversion to carbon dioxide and water in the Krebs cycle.
Other common polyesters include poly(E-caprolactone ),
polyvalerolactone, polydioxanone, and their blends and
copolymers.
Furthermore, although certain drugs are intended for
systemic therapy, many are most effective if targeted to or
placed within a specific site. To this end, drugs are routinely
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SUMMARY
The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This surmnary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
s=ary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the feature
(s) mentioned; likewise, those features can be applied to
other embodiments of the presently-disclosed subject matter, whether listed in this surmnary or not. To avoid excessive repetition, this surmnary does not list or suggest all
possible combinations of such features.
In some implementations of the presently-disclosed subject matter, a compound is provided that comprises an
initiator and an active agent that is covalently bonded to the
initiator through a ring-opening polymerization process, an
atom-transfer radical polymerization process, a Michael
addition reaction, or a ring-opening metathesis polymerization process. In some implementations the initiator comprises one or more hydroxyl groups configured to react and
bind to the active agent, and exemplary initiators can include
methoxypoly(ethylene glycol) (mPEG). In some implementations the active agent includes a lactone group, and exemplary active agents include statins, such as simvastatin. In
this regard, in some implementations the compounds include
a molar ratio of the initiator to the active agent is about 1: 1
to about 1:100.

US 9,433,638 Bl
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In some implementations the compounds are a polymer
that includes a linear or a branched structure. In some
instances the compounds can include a molecular weight of
about 500 Da to about 80 kDa. Exemplary compounds can
further comprise a targeting agent that is selective for a
target substance.
In some implementations the compound is a copolymer,
and in specific embodiments the compound is a diblock
copolymer. For instance, certain embodiments of the present
compounds include the formula:

FIG. 4 includes a graph showing the polydispersity (PDI)
of mPEG-polysimvastatin copolymers that were synthesized
at different temperatures as a function of time.
FIG. 5 includes a graph showing a 1 H-NMR analysis of
a mPEG-polysimvastatin copolymer.
FIG. 6 includes a graph showing fourier transform infrared (FTIR) spectra of (a) mPEG, (b) simvastatin, (c) a
simvastatin and mPEG blend (1 00: 1), and (d) a purified
mPEG-polysimvastatin copolymer.
FIG. 7 includes a schematic diagram showing a hydrolytic
degradation mechanism of a mPEG-poly(simvastatin) copolymer that results in the release of simvastatin molecules.
FIG. 8 includes a graph showing the change in absorbance
of a degrading mPEG-simvastatin copolymer as a function
of time in 1 M NaOH and in phosphate buffered saline
(PBS).
FIG. 9 includes images showing histological differences
four weeks post-implantation in woven bone layers that
were been treated with either no drug (blank) or with an
embodiment of the present simvastatin-loaded compounds
(loaded).
FIG. 10 includes a graph showing the thickness of woven
bone layers formed over calvarias that were treated with
either no drug (blank) or with an embodiment of the present
simvastatin-loaded compounds (loaded).
FIG. 11 includes a graph showing the new bone area and
percentage of new formed mature bone formed over calvarias that were treated with either no drug (blank) or with an
embodiment of the present simvastatin-loaded compounds
(loaded).
FIG. 12 includes a schematic diagram showing an anionic
ring-opening polymerization reaction to form poly(ethylene
glycol)-block-poly(simvastatin).
FIG. 13A includes a gel permeation chromatogram showing the peaks of an embodied compound synthesized with
triazabicyclodecene (TBD) as well as the peaks of the initial
reactants simvastatin and 550 Da mPEG.
FIG. 13B includes a gel permeation chromatogram showing the peaks of an embodied compound synthesized with
triazabicyclodecene (TBD) as well as the peaks of the initial
reactants simvastatin and 2 kDa mPEG.
FIG. 13C includes a gel permeation chromatogram showing the peaks of an embodied compound synthesized with
stannous octoate as well as the peaks of the initial reactants
simvastatin and 5 kDa mPEG.

°

1

15

OYc0

wherein n is about 1 to about 44 and m is about 1 to about
258.
The presently-disclosed subject matter also provides
methods for making a compound. In some implementations
the methods for making a compound include providing an
initiator, mixing an active agent with the initiator to form a
mixture, adding a catalyst to the mixture, and then reacting
the mixture via a ring-opening polymerization process to
form a compound that includes the initiator and the active
agent. In some implementations the catalyst is selected from
a metallic catalyst, an enzymatic catalyst, an organic catalyst, and combinations thereof.
Further still, the presently-disclosed subject matter provides methods for treating a wound in a subject with the
presently-disclosed compounds. In some implementations,
the methods for treating a wound comprise administering a
composition to the wound of a subject, the composition
including an initiator and an active agent that is covalently
bonded to the initiator through a ring-opening polymerization. In some implementations the wound is a bone wound,
a skin wound, or a combination thereof. Also, in some
implementations the step of administering a composition
includes contacting the wound with the composition.
Additional features and advantages of the present invention will also become evident to those of ordinary skill in the
art after a study of the description, figures, and non-limiting
examples in this document.
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DESCRIPTION OF THE DRAWINGS
Illustrative aspects of embodiments of the present invention will be described in detail with reference to the following figures wherein:
FIG. 1 includes a schematic diagram showing a ringopening polymerization reaction between simvastatin and
poly(ethylene glycol) methyl ether (mPEG) that yields a
mPEG-poly(simvastatin) diblock.
FIG. 2 includes a graph showing molecular weights of
mPEG-polysimvastatin copolymers analyzed by gel permeation chromatography (GPC).
FIG. 3 includes a graph showing the molecular weights of
mPEG-polysimvastatin copolymers that were synthesized at
different temperatures as a function of time.
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DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding, and no unnecessary limitations are to be
understood therefrom.
The presently-disclosed subject matter includes compounds that comprise polymeric prodrugs. More specifically, embodiments of the present compounds include an
initiator and an active agent, wherein the active agent is
covalently bonded to the initiator through a ring-opening
polymerization process, an atom-transfer radical polymer-

US 9,433,638 Bl
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ization process, a Michael addition reaction, a ring-opening
metathesis polymerization process, or a combination
thereof.
The present inventors have conceived the present polymeric prodrugs to solve some of the long-felt problems
associated with known polymeric drug compositions.
Embodiments of the present compounds are formed via a
ring-opening polymerization process to combine an initiator,
an active agent, and, optionally, other substances. Embodiments of the compounds can thus form biodegradable compositions that degrade to release active forms of the active
agents. The present compounds therefore differ from current
polymeric drug formulations, which typically consist of
drugs that are mixed with a polymeric material, encapsulated in a polymeric material, or are conjugated to a polymeric material via functional groups located along the
polymer's backbone. Thus, while the present compounds are
themselves comprised of active agents, currently known
materials simply include a bioinert polymer that serves as an
agent carrier.
In this regard, the mechanisms of polymer degradation
and drug release of the present compounds can be the same
since the chemical structure of the compound is comprised
of the polymeric prodrug. In other words, since the active
agent is directly incorporated into the present compounds,
degradation of the compounds releases the active agent into
the surrounding environment. Furthermore, polymerization
of the prodrug (e.g., simvastatin) eliminates certain limitations on the number of prodrug molecules provided by the
compounds relative to current polymer-prodrug systems. As
a result, relatively increased concentrations of active agents
can be provided in the present compounds, which can
provide more efficient therapeutic effects and localized
release of active agents.
In certain embodiments the presently-disclosed subject
matter includes novel compounds and methods for making
the same that include a biodegradable poly(ethylene glycol
methyl ether-block-simvastatin) copolymer. Within a physiological environment, the copolymer can degrade by hydrolysis of ester bonds into the osteogenic biomolecules of
simvastatin for therapeutic treatment.
The terms "biodegradable," "degradable," or the like are
used interchangeably herein to refer to compounds and
compositions that degrade under physiological conditions
and/or are metabolized or excreted with little to no adverse
effects to a subject. In certain embodiments, the compounds
are metabolized or excreted without permanent damage to
the subject. Biodegradable compounds can be hydrolytically
degradable, can require cellular and/or enzymatic action to
fully degrade, or both. Biodegradable compounds also
include compounds that are broken down within cells.
Degradation may occur by hydrolysis, oxidation, enzymatic
processes, phagocytosis, or other processes. Degradation
rates for compounds can vary, and may be on the order of
hours, days, weeks, months, or years, depending on the
embodiment of the compound. In some embodiments the
compounds and compositions include prodrugs that can
degrade to form active agents.
Additionally or alternatively, embodiments of the presently-disclosed compounds can be biocompatible. The term
"biocompatible" as used herein describes a characteristic of
compounds that do not typically induce undesirable or
adverse side effects when administered in vivo. For
example, biocompatible compounds may not induce side
effects such as significant inflammation and/or acute rejection. It will be recognized that "biocompatibility" is a
relative term, and some side effects can be expected even for

some compounds that are biocompatible. In some embodiments, a biocompatible compounds does not induce irreversible side effects, and in some embodiments a compound
is biocompatible if it does not induce long term side effects.
One test to determine biocompatibility is to measure
whether cells die upon being exposed a composition in vitro.
For instance, a biocompatible compound may cause less
than about 30%, 20%, 10%, or 5% cell death.
As stated above, embodiments of the present compounds
can comprise an initiator and an active agent. The initiator
is not particularly limited except that it must be a capable of
forming a polymeric material with the active agent. In some
embodiments the initiator is a monomer compound that can
undergo a ring-opening polymerization process with the
active agent. For instance, in some embodiments the initiator
comprises one or more hydroxyl groups, and can be referred
to herein as a hydroxylated monomer. In some embodiments
it is preferable that the initiator have one group (e.g.,
hydroxyl group) that can initiate a ring-opening polymerization process, such as methoxypoly(ethylene glycol)
(mPEG).
The type and size of the initiator can also be varied to tune
the characteristics of the resulting compound. In some
embodiments the initiator and/or the active agent has a
hydrophobic character or a hydrophilic character. In a specific embodiments comprising a mPEG initiator, the initiator
has a hydrophilic character. Thus, by tuning the relative
concentration and/or size of the mPEG initiator, the resulting
compound can be imparted with a relatively more hydrophobic or hydrophilic character.
The hydrophilic and hydrophobic characteristics of a
compound can be tuned to, among other things, adjust the
degradation rates of a compound. As described herein, some
embodiments of compounds degrade via hydrolysis. Thus,
for such embodiments, the degradation of the compound can
increase as the hydrophilic character of the compound
increases. In other words, hydrophilic compounds that more
easily attract and absorb water permit can permit a greater
degree of hydrolysis relative to more hydrophobic compounds that repel or at least to not permit water to contact the
compound as easily. For instance, in some embodiments the
relative concentration and/or molecular weight of a hydrophilic mPEG initiator can be increased in a compound to
increase the hydrophilicity and relative degradation rate of
the compound via hydrolysis.
The active agent to be used in embodiments of the
presently-disclosed subject matter is also not particularly
limited so long as it is capable of forming a polymeric
material with the initiator. In this regard, the term "active
agent" is used herein to refer to compounds or entities that
alter, promote, speed, prolong, inhibit, activate, or otherwise
affect biological or chemical events in a subject. Exemplary
active agents include, but are not limited to, osteogenic
agents, osteoinductive agents, and osteoconductive agents,
anti-cancer agents, antibiotics, immunosuppressants, antiviral agents, inhibitors, anti-histamines, anti-parasite agents,
anti-protozoal agents, anti-fungal agents, analgesics, antiinflammatory agents, anti-angiogenic factors, angiogenic
factors, targeting agents, polypeptides, cells, polynucleotides, viruses, and vaccines. In some embodiments, the
bioactive agent is a drug and/or a small molecule, such as a
statin. Similar to the initiator, the active agent can comprise
one or more groups that are suitable for undergoing a
ring-opening polymerization process with the initiator.
In some embodiments the active agent and/or the initiator
is selected to provide the compounds with one or more
osteoconductive, osteoinductive, osteogenic, and osteointe-
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grating properties. The term "osteoconductive" as used
herein refers to the property of a compound or composition
thereof to be receptive to the growth of new bone and
stimulate bone tissue growth. The term "osteoinductive" as
used herein refers to the property of a compound or composition thereof to promote bone growth in surrounding
tissues by recruiting and differentiating mesenchymal stem
cells into osteoblasts, which are cells that have the potential
to form bone. The term "osteogenesis" as used herein refers
to the property of a compound or composition thereof that
can permit osteoprogenitor cells to remain on the compound
or composition so that they may further proliferate, differentiate into characteristic bone cells, and adhere within the
compound or composition. The term "osseointegration" as
used herein refers to the property of a compound or composition thereof that can bind integratively to the surrounding bone tissue.
Exemplary groups include lactone groups. One active
agent that can include lactone groups is simvastatin. Simvastatin is compound that can be used to reduce cholesterol
and that also can possess osteogenic, anti-inflammatory,
angiogenic, and other properties. In some implementations
of the present compounds, simvastatin is administered as a
prodrug in lactone form, and can then undergo hydrolysis by
endogenous esterases to generate a hydroxyacid that acts as
a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitor. By suppressing synthesis of mevalonate,
farnesyl pyrophosphate, and geranylgeranyl pyrophosphate
in a subject, simvastatin can be used to treat various diseases
and conditions. For example, simvastatin can promote bone
formation with increased bone morphogenic protein-2
(BMP-2) expression. It can also inhibit formation and activity of osteoclasts.
Further still, in some embodiments the compounds can act
as and/or further comprise a targeting agent. The term
"targeting agent" refers to a substance that can specifically
bind another substance. In some embodiments a targeting
agent specifically binds to particular proteins. Thus, targeting agents can include agents that specifically bind substances found at a wound site or on tissue to be treated.
Embodiments of the present compounds can comprise any
molecular weight, and those of ordinary skill will appreciate
that the size of the compounds can be modified depending on
the subject to be treated, the wound to be treated, the desired
compound properties, and the like. In some preferred
embodiments the compounds include a linear or branched
structure with a molecular weight of about 500 Da, 1,000
Da, 2,000 Da, 3,000 Da, 4,000 Da, 5,000 Da, 6,000 Da,
7,000 Da, 8,000 Da, 9,000 Da, or 10 kDa. Still further, in
some embodiments the compounds can comprise a linear or
branched structure with a molecular weight of about 15 kDa,
20 kDa, 25 kDa, 30 kDa, 35 kDa, 40 kDa, 45 kDa, 50 kDa,
55 kDa, 60 kDa, 65 kDa, 70 kDa, 75 kDa, 80 kDa, 85 kDa,
90 kDa, 95 kDa, or 100 kDa.
Furthermore, embodiments of the compounds can have
any suitable molar ratio of initiator to the active agent. The
molar ratio can be adjusted depending on the desired properties of the compound (e.g., hydrophilic vs. hydrophobic),
the amount of active agent to be delivered, and the like.
Exemplary compounds can have a molar ratio of active
agent (e.g., simvastatin) to initiator (e.g., mPEG) of about
1:1 to about 100:1, including about 10:1, 20:1, 30:1, 40:1,
50:1, 60:1, 70:1, 80:1, 90:1, or 100:1.
The present compounds can form polymers having various configurations. In some embodiments the polymers are
branched. In other embodiments the polymers are
unbranched. Furthermore, in some embodiments the com-

pounds are a copolymer comprising any suitable orientation
of the initiator and the active agent. The term "copolymer"
as used herein refers to a polymer formed of two or more
different types of monomer units. Furthermore, in some
embodiments the copolymer is an amphipathic block copolymer, wherein a "block" copolymer refers to a structure
comprising one or more sub-combinations of constitutional
or monomeric units. Thus, the term copolymer is inclusive
of block copolymers. In some embodiments the copolymer
is a diblock copolymer comprising two blocks. Exemplary
diblock copolymers can include a block comprised of initiator monomers and a block comprised of active agent
monomers. For example, in embodiments comprising an
mPEG initiator and a simvastatin active agent, the compounds can include the following formula:
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wherein n is about 1 to about 44, and m is about 1 to about
248. The compounds are not limited to diblock copolymers,
and can include alternating copolymers and the like.
By virtue of directly binding the active agent to the
initiator, the present compounds can form prodrugs of an
active agent. The term "prodrug" is used herein to refer to an
inactive or relatively less active form of an active agent that
becomes active through one or more metabolic processes in
a subject. For example, the present compounds can be
administered to a subject as a prodrug that includes an
initiator bound to an active agent, and, by virtue of being
degraded by a metabolic process, the active agent is released
from the compound in its active form. In some instances
hydrolytic degradation of the present compounds converts
the prodrug compounds from an inactive or relatively inactive form to an active form. In specific embodiments hydrolytic degradation releases biologically active simvastatin
from a relatively inactive or less active mPEG-simvastatin
copolymer.
The presently-disclosed subject matter also includes pharmaceutical compositions compnsmg the compounds
described herein as well as a pharmaceutically acceptable
carrier. The term "pharmaceutically acceptable carrier"
refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders
for reconstitution into sterile solutions or dispersions just
prior to use. The compositions can thus be in the form of a
cream, paste, lotion, liquid, or the like.
Proper fluidity can be maintained, for example, by the use
of coating materials such as lecithin, by the maintenance of
the required particle size in the case of dispersions, and by
the use of surfactants. These compositions can also contain
adjuvants such as preservatives, wetting agents, emulsifying
agents and dispersing agents. It can also be desirable to
include isotonic agents such as sugars, sodium chloride and
the like. The compositions can be sterilized, for example, by
filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water
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or other sterile injectable media just prior to use. Suitable
inert carriers can include sugars such as lactose.
Suitable formulations include aqueous and non-aqueous
sterile solutions that can contain antioxidants, buffers, bacteriostats, bactericidal antibiotics, and solutes that render the
compositions isotonic with the bodily fluids of the intended
recipient; and aqueous and non-aqueous sterile suspensions,
which can include suspending agents and thickening agents.
The compositions can take such forms as suspensions,
solutions, or emulsions in oily or aqueous vehicles, and can
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the compositions
can be in powder form for constitution with a suitable
vehicle, e.g., sterile pyrogen-free water, before use.
The compositions can be presented in unit-dose or multidose containers, for example sealed ampoules and vials, and
can be stored in a frozen or freeze-dried (lyophilized)
condition requiring only the addition of sterile liquid carrier
immediately prior to use.
The presently-disclosed subject matter further includes
methods for making a compound. In some embodiments the
methods comprise providing an initiator, mixing an active
agent with the initiator to form a mixture, adding a catalyst
to the mixture, and reacting the mixture to form a compound
that includes the initiator and the active agent. The step of
reacting the mixture to form the compound can comprise
reacting the mixture via a ring-opening polymerization
process.
With respect to the catalyst, various known catalysts may
be utilized. Such catalysts include, but are not limited to,
metallic catalysts, such as stannous octoate, aluminum isopropoxide, and yttrium isopropoxide, enzymatic catalysts,
such as porcine pancreatic and Candida Antarctica lipases,
and organic systems (organic catalysts), such as triazabicyclodecene and carboxylic acids with an alcohol. In some
embodiments the mixture is provided with about 0.5 to 5 wt
% of catalyst. In some embodiments the mixture for preparing the compositions includes about 0.1 to 5 wt% of the
catalyst.
The reaction conditions as well as the reaction duration
can be modified to tune the properties of the resulting
compound. In some embodiments the step of reacting the
mixture is performed at a predetermined temperature. The
predetermined temperature can be, but is not limited to,
temperatures of about 20° C., 30° C., 40° C., 50° C., 60° C.,
70° C., 80° C., 90° C., 100° C., 110° C., 120° C., 130° C.,
140° C., 150° C., 160° C., 170° C., 180° C., 190° C., 200°
C., 210° C., 220° C., 230° C., 240° C., 250° C., or any
temperatures therebetween. In some implementations, the
molecular weight of the resulting compound increases as the
reaction temperature increases.
Similarly, the reaction can be allowed to proceed for a
predetermined time period. The time period can be about 1
to about 25 hours, including about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25
hours. In some embodiments the polydispersity and/or the
molecular weight of the resulting compounds increase as the
reaction time is increased.
Further still, the presently-disclosed subject matter
includes methods for treating a wound in a subject. In some
embodiments the method comprises administering a composition to the wound, the composition including a compound that comprises an initiator and an active agent that is
covalently bonded to the initiator through a ring-opening
polymerization process. The various methods of treatment
that are described herein can utilize any of the compounds
that are described in this paper.

The terms "treatment" or "treating" refer to the medical
management of a subject with the intent to cure, ameliorate,
stabilize, or prevent a disease, pathological condition, or
disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a
disease, pathological condition, or disorder, and also
includes causal treatment, that is, treatment directed toward
removal of the cause of the associated disease, pathological
condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of
symptoms rather than the curing of the disease, pathological
condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely
inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that
is, treatment employed to supplement another specific
therapy directed toward the improvement of the associated
disease, pathological condition, or disorder. In some
embodiments the term treatment refers to wound healing,
tissue regeneration, or the like.
Also, the term "subject" is inclusive of both human and
animal subjects. Thus, veterinary uses are provided in accordance with the presently disclosed subject matter and the
presently-disclosed subject matter provides methods for
preventing oxidative damage in mammals such as humans,
as well as those mammals of importance due to being
endangered, such as Siberian tigers; of economic importance, such as animals raised on farms for consumption by
humans; and/or animals of social importance to humans,
such as animals kept as pets or in zoos. Examples of such
animals include but are not limited to: carnivores such as
cats and dogs; swine, including pigs, hogs, and wild boars;
ruminants and/or ungulates such as cattle, oxen, sheep,
giraffes, deer, goats, bison, and camels; and horses. Also
provided is the treatment of birds, including the treatment of
those kinds of birds that are endangered and/or kept in zoos,
as well as fowl, and more particularly domesticated fowl,
i.e., poultry, such as turkeys, chickens, ducks, geese, guinea
fowl, and the like, as they are also of economic importance
to humans. Thus, also provided is the treatment of livestock,
including, but not limited to, domesticated swine, ruminants,
ungulates, horses (including race horses), poultry, and the
like.
In some embodiments of the present treatment methods,
the step of administering the composition includes contacting the composition with the any surface that can support the
composition. In some embodiments the surface includes a
tissue wound surface. The term "tissue" is used herein to
refer to a population of cells, generally consisting of cells of
the same kind that perform the same or similar functions. In
some embodiments tissue is part of a living organism, and in
some embodiments tissue is tissue excised from a living
organism or artificial tissue. In some embodiments tissue can
be part of skin, bone, an organ, or the like.
Furthermore, the term "wound" is used herein to refer to
any disease, condition, injury, defect, disorder, or the like
present on any tissue that is in need of treatment. The wound
itself can be a bone wound, a skin wound, some other tissue
wound, or a combination thereof. In some embodiments a
wound is bone (tissue) fracture. Thus, the presently-disclosed compounds can be administered to treat bone fractures that are the result of an injury, disease, disorder, or the
like.
The composition can be administered with the compound
in a prodrug form. Accordingly, as the composition that
comprises the compounds degrades (e.g., via hydrolysis)
within a subject, the active agent contained in the compound
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is released into the surrounding environment in its active
form. The delivery of active agent that results from the
degradation of a composition can be beneficial when treating
a localized wound on a subject. Degradation of the composition can also provide a sustained and controllable release
of active agent at a wound site.
Furthermore, the composition may be administered in
several different forms. In some embodiments the composition is administered as a film. The film can be contacted
with a wound on a subject. In other embodiments the
composition is administered as nano- or microparticles, an
oil-in-water emulsion, or as a three-dimensional scaffold.
The scaffold itself can be porous or non-porous. Accordingly, the step of administering the composition, depending
on the type of composition, the wound to be treated, and the
like, can including injecting the composition on to a wound,
contacting the composition on to a wound site, applying the
composition as a paste or liquid on to a wound, or the like.
The present compositions and compounds can also be
used as coating materials to coat medical devices, implants,
or other devices configured to be implanted in or on a
subject. The device can therefore include medical devices,
biomaterials, or both. Devices that have been coated with the
present compounds and compositions can provide a sustained and controlled delivery of active agent. The release of
active agent from a coating can help ameliorate or accelerate
the treatment of an existing wound. The release of active
agent from a coating can also help mitigate adverse effects
that may be caused by the implanted device.

and then at 150° C. for 1 hour in a sand bath. After adding
stannous octoate catalyst, reactions were allowed to proceed
at different temperatures and for different times, with the
reaction vessel continuously purged with nitrogen gas. The
reaction product was precipitated in methylene chloride and
diethyl ether followed by vacuum filtration. Molecular
weights of the resulting polymers were analyzed by gel
permeation chromatography (GPC) (FIG. 2). A distinct
leftward shift can be seen as simvastatin "monomers" were
consumed in the ROP reaction. FIGS. 3 and 4 shows
quantification of the molecular weight and polydispersity of
the polymers as a function of reaction temperature at 24
hours. In these procedures, polymers reaching nearly 80 kDa
were synthesized.
Copolymer molecular weight, composition, and polydispersity were characterized by GPC, by preparing 5 to 10
mg/ml samples in tetrahydrofuran. Select samples were
prepared in deuterated chloroform for supplementary structural analysis by 1 H-NMR (University of Kentucky NMR
Facility; Lexington, Ky.) (FIG. 5). Fourier transform infrared (FTIR) spectroscopy was also be used to evaluate the
ratio of functional groups unique to individual block components of the copolymer and carbonyl peak shift analysis
(FIG. 6).
Degradation kinetics with associated measurement of
released simvastatin-containing molecules were assessed for
films cast from the synthesized copolymers. Following
incubation in a physiological buffer for increasing periods,
mass loss was quantified. FIG. 7 shows a schematic of the
hypothesized degradation mechanism. Degradation studies
were conducted at both physiological (neutral) and alkaline
(up to pH 12) conditions. Over a six week period, slow
polymer degradation with associated slow release of simvastatin was observed (FIG. 8). For 16-18 mg samples, the
cumulative drug amounts released were 108 and 266 flg in
neutral (phosphate-buffered saline, PBS) and alkaline
(NaOH) solutions, respectively. After an initial burst of 59
flg in 24 hr, a zero-order release rate was observed in NaOH
with a constant of 7.4 flg·hr- 1 between 1 and 10 days. A
first-order release rate followed with a constant of 21 d- 1 for
the remainder of the degradation period. In PBS, after an
initial burst of37 flg in 24 hr, 2.5 flg was released during the
following 8 days. A zero-order release constant of 2.1 flg·d- 1
was determined for the remainder of the degradation period.
These degradation/release rates would yield formulations
that can deliver the active agent for periods exceeding one
year.
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EXAMPLES
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The examples may include compilations of data that are
representative of data gathered at various times during the
course of development and experimentation related to the
presently-disclosed subject matter. Furthermore, some of the
examples described herein may be prophetic examples.
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Example 1
This Example describes a process for making exemplary
compounds comprising mPEG and a simvastatin active
agent. This Example also describes procedures conducted to
characterize the synthesized copolymers.
Stam1ous octoate was used for lactone polymerization
given its relatively low cost, low toxicity, and high efficiency. With this reaction, the metal catalyst first forms a
complex with the hydroxyl group of the initiator (i.e.,
mPEG) to form an alkoxide. The more reactive alkoxide
then begins chain propagation by coordinating with the
lactone ring of the monomer, followed by insertion of the
ring into the alkoxide's metal-oxygen bond. Throughout the
process, the alkoxide acts as a nucleophile by attacking the
carbon of the ring's carbonyl group leading to cleavage of
the acyl bond and extended chain formation. FIG. 1 shows
a simplified representation of the exemplary simvastatin
ROP reaction.
Methoxypoly( ethylene glycol) (mPEG) served as initiator
in the ring-opening polymerization (ROP) reactions. Advantages of mPEG include that it comprises a single hydroxyl
functionality and a boiling point suitable for the higher
temperature reactions that can obtain higher molecular
weight polymer.
The initial synthesis began with heating a 1:100 molar
ratio of 5 kDa mPEG to simvastatin at 120° C. for 2 hours
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This Example describes procedures to evaluate the efficacy of simvastatin-containing materials for treating bone
wounds.
Simvastatin-based films are studied in a supracalvarial
implantation model to assess osteogenic effects of simvastatin released from an erodible polymer system. This model
enables testing of a material's ability to enhance formation
of bone from existing bone surfaces outward (i.e., appositional bone formation). For this purpose, blank (no drug) and
simvastatin-releasing implants were placed on the exposed
calvarium, from which the periosteum containing osteoprogenitor cells had been displaced.
Intimately opposed to the pre-existing lamellar bone of
the calvarium was a layer of newly formed woven bone. The
thickness of this layer depended on type of device. In the
blank (no-drug control) animals, a low level of bone activity
was observed, whereas simvastatin-loaded release devices
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stimulated formation of much more woven bone over the
mature, lamellar calvarial bone (FIG. 9). Quantitatively,
whereas disturbing the periosteum stimulated an average of
100 f.Ull of woven bone formation, controlled release
enhanced bone formation by over 110% (p<0.05) (FIG. 10).
FIG. 11 shows the total area of new bone and the percentage
of mature matrix relative to total bone. Simvastatin-loaded
implants elicited 163% larger new bone area compared to
controls, and the percentage of mature bone matrix (26%)
was also higher than that of the controls (21%) (p<0.05).

Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although many
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a prodrug" includes a plurality of such prodrug, and
so forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about." Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations in some embodiments of ±20%, in some embodiments
of ±10%, in some embodiments of ±5%, in some embodiments of ±1 %, in some embodiments of ±0.5%, and in some
embodiments of ±0.1% from the specified amount, as such
variations are appropriate to perform the disclosed method.
It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
Throughout this application, various publications are referenced. All such references, including the follow listed
references, are incorporated herein by reference.
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Example 3
This Example describes another exemplary process for
synthesizing an embodiment of the present compounds
using triazabicyclodecene (TBD) as a catalyst. Unless stated
otherwise, the same synthesis procedure described in
Example 1 was followed.
Triazabicyclodecene was selected was selected as the
organic system to be used as a catalyst because of its efficient
performance at ambient temperatures, ability to work without the need of a co-catalyst, and accessibility. The ringopening polymerization mechanism ofTBD is anionic (FIG.
12). Without being bound by theory, the amidine imine
nitrogen of the nucleophilic catalyst attacks the carbonyl
group on the lactone ring of simvastatin to form a temporary
intermediate as the acyl bond is broken. The secondary
amine within the catalyst activates or becomes attracted to
the alcohols within the reaction mixture (i.e., both on mPEG
and the propagating polysimvastatin block) to form the
mPEG-poly(simvastatin) diblock copolymer through hydrogen bonding.
The results showed that TBD was able to form poly
(ethylene glycol)-block-poly(simvastatin) with efficiency in
polymerization using 550 Da and 2 kDa mPEG. A leftward
shift of the polymer peak or shoulder is seen relative to the
mPEG peaks, indicating an increase in overall molecular
weight of the chains, and hence, growth of the poly(simvastatin) block (FIGS. 13A to 13C). Table 1 summarizes
molecular weight and polydispersity results for the components and copolymers synthesized.
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TABLE 1

REFERENCES

MW comparisons of the diblock copolymers using 550 Da,
2 kDa and 5 kDa mPEG measured via GPC.

Sample
simvastatin
550 Da mPEG
2 kDa mPEG
5 kDa mPEG
550 Da mPEGpoly(simvastatin)
100:2 via TBD
2kkDa mPEGpoly(simvastatin)
100:2 via TBD
5 kDa mPEGpoly(simvastatin)
100:1 via
stannous

Mn (Da)

Mw(Da)

MJMn

300
470
3200
8300
6500

320
560
3400
8800*
10400

1.0
1.2
1.1
1.1
1.6

12700

15200

1.2

13100

29500

2.3

45

%of crude
product
50

21

9.2

55

62
60

*The GPC molecular weight of mPEG registered higher than the expected value because
its chemistry differs from the polystyrene standards used for calibration.

While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
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